# US 2018/0021403 A1 · Combination Therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021403 A1
- Document ID: US20180021403A1
- Status: Published application
- Kind: A1
- Application number: 15/523,188
- Filed: 2015-10-27
- Published: 2018-01-25
- Earliest claimed: 2014-10-30
- Assignees: Big Dna Ltd
- Applicants: Big Dna Ltd
- Inventors: John Bernard MARCH; Ewan Mclntosh CLARK
- Web page: https://patentgrep.com/patent/US20180021403A1

## CPC

- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/69: Boron compounds
- A61K 38/005: {Enzyme inhibitors (protease inhibitors A61K38/55)}
- A61K 38/05: Dipeptides
- A61K 38/06: Tripeptides
- A61K 38/07: Tetrapeptides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a combination comprising a proteasome inhibitor and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. In particular, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: a boronate, an epoxyketone, a peptide aldehyde and a β-lactone protease inhibitor; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. More particularly, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: bortezomib, delanzomib, ixazomib, carfilzomib, oprozomib, MG132 and marizomib; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety.

## Claims

### Claim 1

A combination comprising: (i) a proteasome inhibitor and pharmaceutically acceptable salts thereof; and (ii) a cyclic peptide, wherein the cyclic peptide comprises an exposed Arg-Gly-Asp (RGD) moiety; wherein the ratio of proteasome inhibitor to cyclic peptide component ranges from 1:5000 to 10:1 w/w.

### Claim 2 (depends on 1)

The combination of claim 1, wherein the proteasome inhibitor is a boronate compound.

### Claim 3 (depends on 2)

The combination of claim 2, wherein the boronate compound is selected from the group consisting of: bortezomib, delanzomib and ixazomib.

### Claim 4 (depends on 1)

The combination of claim 1, wherein the proteasome inhibitor is an epoxyketone compound.

### Claim 5 (depends on 4)

The combination of claim 4, wherein the epoxyketone compound is selected from the group consisting of: carfilzomib and oprozomib.

### Claim 6 (depends on 1)

The combination of claim 1, wherein the proteasome inhibitor is a peptide aldehyde compound.

### Claim 7 (depends on 6)

The combination of claim 6, wherein the peptide aldehyde compound is MG132.

### Claim 8 (depends on 1)

The combination of claim 1, wherein the proteasome inhibitor is a β-lactone protease inhibitor compound.

### Claim 9 (depends on 8)

The combination of claim 8, wherein the β-lactone protease inhibitor compound is marizomib.

### Claim 10 (depends on 1)

The combination of claim 1, wherein the cyclic peptide has the structure:
wherein:
Ra, Rb and Rc are amino acid side-chain residues;
Rd are each independently selected from the group consisting of H, C1 alkyl, C2 alkyl and C3 alkyl;
m is 0, 1 or 2;
n is 0, 1 or 2;
provided that the value of n+m is 0, 1 or 2.

### Claim 11 (depends on 10)

The combination of claim 10, wherein the cyclic peptide has the structure;
wherein:
Ra, Rb and Rc are amino acid side-chain residues;
m is 0, 1 or 2;
n is 0, 1 or 2;
provided that the value of n+m is 0, 1 or 2.

### Claim 12 (depends on 10)

The combination of claim 10, wherein Ra, Rb and Rc are amino acid side-chain residues of alanine, cysteine, aspartic acid, glutamic acid, phenylalanine, glycine, histidine, isoleucine, lysine, leucine, methionine, asparagine, proline, glutamine, arginine, serine, threonine, valine, tryptophan, tyrosine, selenocysteine or pyrrolysine.

### Claim 13 (depends on 10)

The combination of claim 10, wherein in is 0 and n is 0; m is 1 and n is 0; or m is 0 and n is 1.

### Claim 14 (depends on 10)

The combination of claim 10, the cyclic peptide component has a structure:

### Claim 15 (depends on 10)

The combination of claim 10, wherein each amine nitrogen of the amino acid of the amino acid residues of the cyclic peptide component can be independently mono-alkylated.

### Claim 16 (depends on 10)

The combination of claim 10, the cyclic peptide component is cilengitide, i.e. has the structure:

### Claim 17 (depends on 1)

The combination of claim 1, for use as a medicament.

### Claim 18 (depends on 1)

The combination of claim 1, for use in the treatment of a disorder selected from the group consisting of: an oncology disorder; a neoplasia; mantle cell lymphoma; multiple myeloma (e.g. metastatic multiple myeloma); lung cancer; non-small cell lung cancer (e.g. metastatic non-small cell lung cancer, non-small cell lung carcinoma or metastatic non-small cell lung cancer); small cell lung carcinoma; solid tumours; lymphoma (e.g. lymphoplasmacytic lymphoma, diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, follicular lymphoma or peripheral T-cell lymphoma); chronic lymphoid leukemia; T-Cell prolymphocytic leukemia; breast cancer (e.g. metastatic breast cancer); cervical cancer; colorectal cancer; colon cancer; melanoma; prostate cancer (e.g. hormone refractory prostate cancer); pancreatic cancer (e.g. metastatic pancreatic cancer); ovarian cancer; glioblastoma (e.g. glioblastoma multiforme); head squamous cell carcinoma; neck squamous cell carcinoma; amyloidosis (e.g. primary systemic amyloidosis); bone disorders; haematological malignancies; graft-versus-host disease, Waldenström's Macroglobulinaemia, Smoldering Myeloma and monoclonal gammopathy of unknown significance (MGUS), or a combination thereof.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising the combination of claim 1 and a pharmaceutically acceptable excipient.

### Claim 20

A kit comprising as separate components: (i) a proteasome inhibitor and pharmaceutically acceptable salts thereof; and (ii) a cyclic peptide, wherein the cyclic peptide comprises an exposed Arg-Gly-Asp (RGD) moiety.

### Claim 21

A use of a cyclic peptide, wherein the cyclic peptide comprises an exposed Arg-Gly-Asp (RGD) moiety, for improving the therapeutic activity of a proteasome inhibitor and pharmaceutically acceptable salts thereof.
